These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 5300097)

  • 41. [Four drug combination including Ethambutol and early switching to entirely new regimen in initial treatment of pulmonary tuberculosis].
    Kekkaku; 1970 Jul; 45(7):219-26. PubMed ID: 5449509
    [No Abstract]   [Full Text] [Related]  

  • 42. [Th 13-14 and PZA and CS in the treatment of chronic cavitary tuberculosis with bacterial resistance to classic antibacterial drugs].
    Zunić D
    Tuberkuloza; 1966; 18(5):429-40. PubMed ID: 16296047
    [No Abstract]   [Full Text] [Related]  

  • 43. Intermittent chemotherapy.
    Tubercle; 1967 Mar; 48(1):58-61. PubMed ID: 4166513
    [No Abstract]   [Full Text] [Related]  

  • 44. [Studies on the effect of antituberculosis agents against tubercle bacilli in the resting state, using streptomycin-dependent strain (18-b). I. Studies in vitro].
    Ota Y
    Kekkaku; 1971 Aug; 46(8):295-301. PubMed ID: 4328204
    [No Abstract]   [Full Text] [Related]  

  • 45. [Experimental therapy with so-called "minor" tuberculostatics].
    Freerksen E
    Wien Med Wochenschr; 1966 Oct; 116(42):874-7. PubMed ID: 6005730
    [No Abstract]   [Full Text] [Related]  

  • 46. [Urgent problems of antibacterial treatment of pulmonary tuberculosis].
    Pilipchuk NS
    Vrach Delo; 1981 Jan; (1):47-9. PubMed ID: 7010782
    [No Abstract]   [Full Text] [Related]  

  • 47. [The effect of different combinations of antibacterial preparations on the activity of several enzymes in the tissues of guinea pigs with experimental tuberculosis].
    Izabolinskaia RM; Kruchakova FA; Polner RA
    Vopr Med Khim; 1973; 19(5):462-7. PubMed ID: 4363032
    [No Abstract]   [Full Text] [Related]  

  • 48. Urogenital tuberculosis.
    Mangelson NL; Saunders JC; Brosman SA
    J Urol; 1970 Aug; 104(2):309-14. PubMed ID: 4988649
    [No Abstract]   [Full Text] [Related]  

  • 49. [Endocavernous treatment of caverns with atypical Mycobacteria].
    Neef W
    Z Erkr Atmungsorgane Folia Bronchol; 1970 Jun; 131(5):385-9. PubMed ID: 5210837
    [No Abstract]   [Full Text] [Related]  

  • 50. Tuberculosis treatment: dangerous regimens?
    Rieder HL; Arnadottir T; Trébucq A; Enarson DA
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):1-3. PubMed ID: 11263509
    [No Abstract]   [Full Text] [Related]  

  • 51. [Experimental study of secondary tuberculostatic preparations in view of the resistance of mycobacteria to the primary drugs].
    Uvarova OA; Zemskova ZS; Stukalova BIa; Afanas'eva IuP
    Farmakol Toksikol; 1967; 30(4):474-7. PubMed ID: 4877410
    [No Abstract]   [Full Text] [Related]  

  • 52. [Comparison of combination therapy of Capreomycin, ethionamide and cycloserin with that of kanamycin, ethionamide and cycloserin for the retreatment of pulmonary tuberculosis].
    Kitamoto O; Oka S; Kawamori Y; Gomi J; Sugiyama K
    Saishin Igaku; 1970 Jul; 25(7):1546-55. PubMed ID: 5451178
    [No Abstract]   [Full Text] [Related]  

  • 53. Is the treatment of WHO category I tuberculosis with 2HRZE/6HE a defensible practice?
    Long R; Scalcini M
    Int J Tuberc Lung Dis; 1999 Sep; 3(9):747-8. PubMed ID: 10488879
    [No Abstract]   [Full Text] [Related]  

  • 54. Rifampicin in daily and intermittent treatment of experimental murine tuberculosis, with emphasis on late results.
    Grumbach F; Canetti G; Le Lirzin M
    Tubercle; 1969 Sep; 50(3):280-93. PubMed ID: 4981497
    [No Abstract]   [Full Text] [Related]  

  • 55. [Efficiency of interrupted therapy of tuberculosis (experimental study)].
    Drabkina RO; Ginzburg TS
    Antibiotiki; 1972 Jun; 17(6):555-60. PubMed ID: 5045922
    [No Abstract]   [Full Text] [Related]  

  • 56. [A study on experimental mycobacterioses provoked by atypical mycobacteria. 2. Combined antituberculous chemotherapy against conventional mice infected intravenously with Mycobacterium intracellulare (author's transl)].
    Kuze F; Lee Y; Maekawa N; Suzuki Y
    Kekkaku; 1979 Sep; 54(9):453-60. PubMed ID: 502152
    [No Abstract]   [Full Text] [Related]  

  • 57. Comparative study of biweekly streptomycin and isoniazid with daily P.A.S. and isoniazid regimens in the treatment of pulmonary tuberculosis.
    Mathur JB; Bahadur P; Agnihotri CB
    J Indian Med Assoc; 1967 Aug; 49(4):162-5. PubMed ID: 5594009
    [No Abstract]   [Full Text] [Related]  

  • 58. Turning intermittent regimens into daily regimens using blister-packs. An exploration in murine tuberculosis.
    Guy A; Dickinson JM; Mitchison DA
    Tuber Lung Dis; 1993 Oct; 74(5):310-6. PubMed ID: 8260664
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens.
    Daniel N; Lounis N; Ji B; O'Brien RJ; Vernon A; Geiter LJ; Szpytma M; Truffot-Pernot C; Hejblum G; Grosset J
    Am J Respir Crit Care Med; 2000 May; 161(5):1572-7. PubMed ID: 10806157
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.